GBT Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 4.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Global Blood Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Global Blood Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Global Blood Therapeutics Share Price & Price History
Current Price: $68.49
Price Change: +0.30 (1.20%)
As of 11/2/2022 01:00 AM ET
Global Blood Therapeutics Insider Trading History
Global Blood Therapeutics Institutional Trading History
Data available starting January 2016
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Read More on Global Blood Therapeutics
Today's Range
Now: $68.49
52 Week Range
Now: $68.49
Volume
74 shs
Average Volume
2,065,836 shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.45